HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $4,319,000 | -34.3% | 500,449 | -27.9% | 0.30% | -26.3% |
| Q1 2016 | $6,576,000 | -22.0% | 694,436 | +42.8% | 0.40% | -14.8% |
| Q4 2015 | $8,427,000 | +29.0% | 486,276 | 0.0% | 0.47% | +111.2% |
| Q3 2015 | $6,531,000 | -57.0% | 486,276 | -27.7% | 0.22% | -2.6% |
| Q2 2015 | $15,194,000 | +25.0% | 672,883 | -21.0% | 0.23% | -66.0% |
| Q1 2015 | $12,157,000 | -37.3% | 851,305 | -57.7% | 0.68% | -30.2% |
| Q4 2014 | $19,398,000 | -47.4% | 2,010,186 | -50.4% | 0.97% | -48.9% |
| Q3 2014 | $36,906,000 | -18.0% | 4,055,590 | -11.0% | 1.90% | -22.0% |
| Q2 2014 | $45,014,000 | -16.0% | 4,556,090 | +8.0% | 2.44% | -20.6% |
| Q1 2014 | $53,600,000 | -15.2% | 4,218,800 | 0.0% | 3.07% | -17.3% |
| Q4 2013 | $63,240,000 | +26.7% | 4,218,800 | -6.7% | 3.71% | +9.2% |
| Q3 2013 | $49,899,000 | +36.4% | 4,519,800 | -1.8% | 3.40% | +38.1% |
| Q2 2013 | $36,582,000 | – | 4,601,500 | – | 2.46% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SNYDER CAPITAL MANAGEMENT L P | 4,324,232 | $165,185,662 | 3.73% |
| Steamboat Capital Partners, LLC | 196,898 | $7,521,504 | 2.79% |
| 2Xideas AG | 600,799 | $22,950,522 | 2.54% |
| BERNZOTT CAPITAL ADVISORS | 171,808 | $6,563,066 | 2.26% |
| Redwood Investments, LLC | 328,459 | $12,547,134 | 1.70% |
| Mesirow Institutional Investment Management, Inc. | 380,415 | $14,531,853 | 1.47% |
| Granite Investment Partners, LLC | 856,253 | $32,708,865 | 1.37% |
| Penn Capital Management Company, LLC | 324,707 | $12,453,211 | 1.28% |
| EFG Asset Management (North America) Corp. | 137,739 | $5,262,319 | 1.25% |
| First Light Asset Management, LLC | 313,536 | $11,977,075 | 1.14% |